Friday, 7 July 2017

Recent Research into the Multiple Sclerosis - Pipeline Review, H1 2017

Multiple Sclerosis - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.
Complete report available @ Multiple Sclerosis - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 30, 32, 1, 168, 34 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 47 and 2 molecules, respectively.
Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
2-BBB Medicines BV 4D Pharma PLC AB Science SA AbbVie Inc Abion Inc Ablynx NV Abzena Plc Acorda Therapeutics Inc Actelion Ltd Adamas Pharmaceuticals Inc Addex Therapeutics Ltd Adhaere Pharmaceuticals Inc Aegis Therapeutics LLC Affectis Pharmaceuticals AG AiCuris GmbH & Co KG Alkermes Plc Allergan Plc Alpha Cancer Technologies Inc Alvotech Iceland Amarna Therapeutics BV Anavex Life Sciences Corp Antisense Therapeutics Ltd Aphios Corp Apitope International NV ARA Healthcare Pvt Ltd Argos Therapeutics Inc Arrien Pharmaceuticals LLC Artielle ImmunoTherapeutics Inc Arven Ilac Asterias Biotherapeutics Inc AstraZeneca Plc Atara Biotherapeutics Inc Athersys Inc Atlantic Bio Sci LLC Axxam SpA Bio-Cancer Treatment International Ltd BioApex sro Biocad Biocon Ltd Biogen Inc BioHealthonomics Inc Biomar Microbial Technologies Bionovis SA Bionure Farma SL Biovista Inc Bolder Biotechnology Inc BrainStorm Cell Therapeutics Inc Bristol-Myers Squibb Company CASI Pharmaceuticals Inc Catalyst Pharmaceuticals Inc Celgene Corp Cell Cure Neurosciences Ltd Cell2B Advanced Therapeutics SA Cinnagen Co Cognosci Inc Coherus BioSciences Inc Commence Bio Inc Compugen Ltd Connexios Life Sciences Pvt Ltd Critical Outcome Technologies Inc CuraVac Inc Cyxone AB DanDrit Biotech A/S Denceptor Therapeutics Ltd Dimerix Bioscience Pty Ltd Eisai Co Ltd Eli Lilly and Company Evgen Pharma Plc Evotec AG F. Hoffmann-La Roche Ltd Flex Pharma Inc Forward Pharma A/S FPRT Bio Inc Gemac SA Genervon Biopharmaceuticals LLC GeNeuro SA Genzyme Corp GlaxoSmithKline Plc Glialogix Inc Hansa Medical AB Harbor Therapeutics Inc Humabs BioMed SA Hutchison China MediTech Ltd Immune Response BioPharma Inc Immune Therapeutics Inc Immungenetics AG Immunwork Inc Inception Sciences Inc Innate Immunotherapeutics Ltd Inovio Pharmaceuticals Inc Io Therapeutics Inc Jyant Technologies Inc Kadimastem Ltd Kadmon Corp LLC KAHR medical Ltd KaloBios Pharmaceuticals Inc Kancera AB Karo Pharma AB Karyopharm Therapeutics Inc Kissei Pharmaceutical Co Ltd KPI Therapeutics Inc Kyorin Pharmaceutical Co Ltd Lead Discovery Center GmbH LFB SA Lipocure Ltd MacroGenics Inc Mapi Pharma Ltd Marathon Pharmaceuticals LLC MedAnnex Ltd MedDay SA Medestea Research & Production SpA MedImmune LLC Merck KGaA Meta-IQ ApS Mitochon Pharmaceuticals Inc Mitotech SA Mitsubishi Tanabe Pharma Corp Mochida Pharmaceutical Co Ltd MorphoSys AG Mount Tam Biotechnologies Inc Neuralstem Inc Neuren Pharmaceuticals Ltd Neurofx Inc Neuronax SAS New World Laboratories Inc Novartis AG Nuevolution AB Numab Innovation AG Ogeda SA Omeros Corp OncoImmune Inc Opexa Therapeutics Inc Oryzon Genomics SA OSE Immunotherapeutics Pangen Biotech Inc. Parvus Therapeutics Inc Pfenex Inc Pfizer Inc Pharmaxis Ltd ProNoxis AB Prothena Corp Plc Quimatryx SL ReceptoPharm Inc RedHill Biopharma Ltd RegeneRx Biopharmaceuticals Inc Regenesance BV Renovo Neural Inc Resverlogix Corp ReveraGen BioPharma Inc Rigel Pharmaceuticals Inc Rock Creek Pharmaceuticals Inc Rodos BioTarget GmbH SanBio Inc Santhera Pharmaceuticals Holding AG Sareum Holdings Plc Senju Pharmaceutical Co Ltd Sorrento Therapeutics Inc Spherium Biomed SL Symic Biomedical Inc Synthon Holdings BV Teikoku Pharma USA Inc Teva Pharmaceutical Industries Ltd TikoMed AB Tiziana Life Sciences Plc Toleranzia AB Topas Therapeutics GmbH TxCell SA Vaccinex Inc Vakzine Projekt Management GmbH Vicore Pharma AB viDA Therapeutics Inc Virogenomics BioDevelopment Inc VivaCell Biotechnology Espana SL Xenetic Biosciences Inc XL-protein GmbH Yungjin Pharm Co Ltd Zydus Cadila Healthcare Ltd
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home